Inovio Pharma (INO) Misses Q3 EPS by 14c

Inovio Pharma (NASDAQ: INO) reported Q3 EPS of ($0.39), $0.14 worse than the analyst estimate of ($0.25). Revenue for the quarter came in at $2.6 million versus the consensus estimate of $9.36 million.

For earnings history and earnings-related data on Inovio Pharma (INO) click here.

You May Also Be Interested In

• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• The LGL Group (LGL) Misses Q2 EPS by 8c
• Four Tree Island Advisory calls DoubleDown $11.25 offer too low